Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia: a multicenter, non-selected, retrospective cohort study

Bibliographic Details
Title: Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia: a multicenter, non-selected, retrospective cohort study
Authors: Suhyeon Kim, Jiye Jung, Seo-Yeon Ahn, Mihee Kim, So Yeon Jeon, Chang-Hoon Lee, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Byung-Soo Kim, Hyeoung-Joon Kim, Jae-Yong Kwak, Yong Park, Jae-Sook Ahn, Ho-Young Yhim
Source: Frontiers in Oncology, Vol 14 (2024)
Publisher Information: Frontiers Media S.A., 2024.
Publication Year: 2024
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: acute promyelocytic leukemia, all-trans retinoic acid, early mortality, prognosis, risk stratification, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: IntroductionDespite the current effective treatments for acute promyelocytic leukemia (APL), early mortality (EM), defined as death within 30 days of presentation, is a major hurdle to long-term survival.MethodsWe performed a multicenter retrospective study to evaluate the incidence and clinical characteristics of EM in patients with newly diagnosed APL and to develop a risk stratification model to predict EM.ResultsWe identified 313 eligible patients diagnosed between 2000 and 2021 from five academic hospitals. The median age was 50 years (range 19-94), and 250 (79.9%) patients were 24 hours of presentation (HR, 2.95). Based on these factors, patients were stratified into three categories with a significantly increasing risk of EM: 4.1% for low risk (54.3%; no risk factors; HR 1), 18.5% for intermediate risk (34.5%; 1 factor; HR 4.81), and 40.5% for high risk (11.2%; 2-3 factors; HR 13.16).DiscussionThe risk of EM is still not negligible in this era of ATRA-based therapies. Our risk model serves as a clinically useful tool to identify high-risk patients for EM who may be candidates for novel treatments and aggressive supportive strategies.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1307315/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2024.1307315
Access URL: https://doaj.org/article/08d6174f21f24c38aeeff570d43c37d0
Accession Number: edsdoj.08d6174f21f24c38aeeff570d43c37d0
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2024.1307315
Published in:Frontiers in Oncology
Language:English